Hester Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/01/2026 ,inter alia, to consider and approve unaudited standalone and ....
HESTERBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Hester Biosciences has informed the stock exchanges that its Board of Directors will meet on Friday, 30 January 2026. The agenda includes considering and approving the unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025 (Q3 FY26). This is a routine regulatory filing under SEBI Listing Regulations, and no financial numbers have been disclosed yet. The results are expected to be announced after the board meeting concludes.
This is a procedural filing with no immediate impact on shareholders. Investors should watch for the actual Q3 results on or after 30 January 2026 for insights into the company's revenue, profitability, and margins.